Back to results
US 10,941,109 B2Granted
Compositions and methods of treatment using a BCAT1 inhibitor
AssigneeErgon Pharmaceuticals LLC
InventorAdonia E. Papathanassiu
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compounds and methods that inhibit the cytosolic form of BCAT1.
Claims8
A compound of Formula (1):
- or a pharmaceutically acceptable salt of the compound, wherein:
- T is —C(═O)—;
- R1 is a phenyl group substituted with one substituent selected from the group consisting of halo, CN, —COOH, —NH2, —NH(CH3), —N(CH3)2, and —CONH2, and optionally further substituted with one or more substituents selected from the group consisting of —C1-C6 alkyl, halo, —OH, alkoxy, —NH2, —COOH, —NH(CH3), —N(CH3)2, and —CONH2;
- R2 is a phenyl, optionally substituted with one or more substituents selected from the group consisting of —C1-C2 alkyl, halo, CN, —COOH, —OH, alkoxy, —NH2, —COOH, —NH(CH3), —N(CH3)2, and —CONH2;
- and
- R3 is hydrogen.
3 more elements
A compound of Formula (1),
- or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or N-oxide,
- where T is —C(═O)—,
- where R1 is CH3, R2 is —CH3, and R3 is —(CH2)2CN, having the structure (8)
A compound of Formula (1),
- or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or N-oxide,
- where T is —C(═O)—,
- where R1 is (a-3), where X is —N or —CH, and R4, R5, R6, and R7 are independently H or —CH3,
- where R2 is a phenyl group, optionally substituted with one or more substituents selected from the group consisting of —C1-C2 alkyl, halo, CN, —COOH, —OH, —C1-C2 alkoxy, —NH2, —COOH, —NH(CH3), —N(CH3)2, and —CONH2;
- and
- where R3 is hydrogen.
3 more elements
Dependencies are inferred from the claim text.